# Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

> **NCT02198326** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBN 4096 BS- in single rising doses
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02198326
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 1999-08
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198326, "Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02198326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*